House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Perspective
The job description for the ideal health care leader in coming years might read something like this:Wanted: Bold, compassionate innovator who unites clinical…
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
The AHA’s Next Generation Leaders Fellowship July 29 announced its 36 fellows for the class of 2026, who will each work with mentors to address a specific…
Headline
The American Society for Health Care Engineering July 28 announced the recipients of its annual member awards during the 2025 Health Care Facilities Innovation…